Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of drugs in diseases such as cancer. Product development is based on Oasmia’s drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that usually require chemical solubilizers for dissolution. The Company's approved product that is using this technology is Apealea (paclitaxel micellar). Apealea has market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region.